Modafinil: the legal and safety record

The 2008 plea: adjudicated, and about marketing

In September 2008, Cephalon — Provigil’s manufacturer — agreed to plead guilty to one misdemeanor count of distributing misbranded drugs under the Food, Drug and Cosmetic Act and to pay $425 million: a $375 million civil settlement, a $40 million criminal fine, and $10 million in forfeiture [1]. Provigil was one of three drugs in the case, alongside Actiq and Gabitril. The government’s description of the Provigil conduct is worth reading exactly: the drug was approved for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder, and Cephalon promoted it for sleepiness, tiredness, decreased activity, and fatigue generally [1]. The everyday-wakefulness pitch — the ancestor of today’s productivity aura — is the court-documented part.

Precision on the instrument: this one is a guilty plea — a criminal adjudication, entered by the company itself — which is exactly what the next matter on this page is not.

The pay-for-delay case: a $1.2 billion settlement, not a verdict

The FTC sued Cephalon in February 2008, alleging that in 2005 and 2006 it paid four generic manufacturers more than $300 million to drop their patent challenges and keep generic modafinil off the market until April 2012 [2][3]. The case ended in 2015 — after the Supreme Court’s FTC v. Actavis decision made reverse-payment settlements reachable under antitrust law, and as the first FTC case resolved under it [2] — when Teva, which had acquired Cephalon in 2012, agreed to make $1.2 billion available as equitable monetary relief under a Stipulated Order for Permanent Injunction and Equitable Monetary Relief entered in June 2015 [3].

Every word of that characterization is doing work. It is a settlement: no court ever adjudicated the antitrust claims, and the company resolved them with no admission of liability — Teva was actively contesting the case, with trial set for June 2015, when it settled [5]. The money is not a fine; it compensates the wholesalers, pharmacies, and insurers alleged to have overpaid, with credit for related private-litigation payments and any remainder to the Treasury [2]. The court’s April 2015 ruling that the FTC could seek disgorgement of past profits was a ruling about available remedies, not a finding that the conduct was illegal [3]. Pages that render this as “Teva found guilty of pay-for-delay” are wrong twice over.

The private track is on the record too. Direct purchasers who sued over the same agreements settled with Cephalon, Teva, and Barr in April 2015 — a $512 million settlement, per Teva’s own SEC filing — and with Mylan in January 2017 [4][5]. The litigation that continued past those settlements ended differently: the Third Circuit vacated the class certification in 2016, and on remand the district court denied certification [4]. An honest record includes that, because it is the part a page built to alarm you would leave out.

The safety record, stated precisely

• Schedule IV, no boxed warning. Modafinil is a Schedule IV controlled substance, and its label carries no boxed warning [6]. Its most serious warning sits in Warnings and Precautions section 5.1: serious rash including Stevens-Johnson Syndrome, toxic epidermal necrolysis, and DRESS, with the instruction to discontinue at the first sign of rash unless it is clearly not drug-related [6]. A label warning and a boxed warning are different instruments; we say which one this is.
• Not approved for children — and the rash is why that matters. In pediatric trials, rash led to discontinuation in roughly 0.8% of patients under 17, including one case of possible SJS; the label states modafinil is not approved for pediatric patients for any indication [6].
• Psychiatric and cardiovascular cautions in the label. Sections 5.5 and 5.7 caution about psychiatric symptoms (postmarketing reports include mania, delusions, hallucinations, and suicidal ideation, many but not all in patients with prior psychiatric history) and cardiovascular events [6].
• No Class I recall (within openFDA’s ~2012-onward coverage window). Two recall records, both Class II and terminated — a repackager’s labeling mix-ups, nothing about the molecule [7].

What this record is not about: you

Modafinil’s off-label life as a focus drug gets written about in two registers — glamor and panic — and this page declines both. The legal record above is about corporate conduct: how the drug was marketed, and how generic competition to it was suppressed. It contains no adjudicated finding about anyone who takes modafinil, and no court has decided that the drug injured any particular patient in these matters. A prescriber writing modafinil off-label today is doing something legal and possibly reasonable — off-label prescribing is legal and common, and what the record changes is only the burden of the question: for a use built outside the approval trials, “what evidence supports this for my situation?” is the question to bring to your prescriber. The approved indications, the label, and the trial record are on our modafinil page, caveats first — and how its approval trials compare to others’ is on our trial-length page.

Common questions

What did Cephalon plead guilty to in 2008?

One misdemeanor count of distributing misbranded drugs — drugs whose labeling lacked adequate directions for use — under the Food, Drug and Cosmetic Act. The resolution, announced by the Department of Justice on 29 September 2008, totaled $425 million: a $375 million civil settlement, a $40 million criminal fine, and $10 million in forfeiture. Three drugs were involved: Actiq, Gabitril, and Provigil (modafinil), which the government said was promoted for sleepiness, tiredness, decreased activity, and fatigue beyond its approved uses.

Is the $1.2 billion FTC resolution a fine?

No, and the difference matters. It is equitable monetary relief under a settlement — a Stipulated Order for Permanent Injunction and Equitable Monetary Relief entered in June 2015 — that resolved the FTC’s 2008 complaint without any admission of liability and without a court ever adjudicating the antitrust claims. The money was directed to compensating wholesalers, pharmacies, and insurers who overpaid for Provigil, with credit for related private-litigation payments and any remainder to the US Treasury.

Is it legal to take modafinil for focus or productivity?

With a prescription, yes — off-label prescribing is legal and common, and it is the marketing of off-label uses by manufacturers that was illegal. Without a prescription the answer changes: modafinil is a Schedule IV controlled substance in the United States, so possessing it without one is a different legal question entirely, and buying it from unregulated online sellers adds product-quality risks no part of this record speaks to.

Does modafinil have a black box warning?

No. The FDA-approved label carries its serious-rash warning — Stevens-Johnson Syndrome, toxic epidermal necrolysis, and DRESS — in the Warnings and Precautions section (5.1), not as a boxed warning. A warning in the label and a boxed warning are different instruments, and pages that blur them are rounding up. The label’s instruction is concrete: discontinue at the first sign of rash unless the rash is clearly not drug-related.

Is modafinil approved for children?

No — for any indication. In pediatric clinical trials, rash leading to discontinuation occurred in approximately 0.8% of patients under 17, including one case of possible Stevens-Johnson Syndrome, versus none on placebo. That trial experience is in the label itself, which states plainly that Provigil is not approved for use in pediatric patients for any indication.

Has modafinil had serious recalls?

No Class I recall — FDA’s most serious category — appears in the openFDA enforcement database (that dataset is reliable only from roughly 2012 onward, so this is a statement about the covered window, not the drug’s whole history). Two records exist, both Class II and both terminated, and both were a repackager’s labeling mix-ups rather than anything about the molecule.

Did anyone prove modafinil harmed patients in these cases?

No, and nothing on this page says otherwise. The 2008 plea was about marketing conduct; the FTC case and the private antitrust litigation were about prices paid by wholesalers, pharmacies, and insurers. None of it adjudicated a claim that modafinil injured any particular patient, and a page that lets you infer otherwise is overreaching — in either direction.

Sources

Last verified 2026-09-08. Corrections change this date.